Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
5Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Aktis Oncology, Inc. (AKTS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
3Distinct source URLs
7High confidence
0.820Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Aktis Oncology, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC
MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC
90%
Pursuant to the Royalty Transfer Agreement, the Company will pay 0.5 % of annual global net sales to each of the Charitable Foundations, for a total of 1.0 % of net sales, subject to customary reduct…
UBS-OPTIMUS-FOUNDATION
UBS-OPTIMUS-FOUNDATION
90%
Pursuant to the Royalty Transfer Agreement, the Company will pay 0.5 % of annual global net sales to each of the Charitable Foundations, for a total of 1.0 % of net sales, subject to customary reduct…
Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY grap…
Aktis Oncology, Inc. Customers
Ticker
Name
Confidence
Evidence
ELI-LILLY
ELI-LILLY
92%
In addition, if Eli Lilly successfully commercializes a therapeutic or diagnostic product under the Collaboration Agreement, Eli Lilly is required to pay us tiered royalties of up to 10% based on ann…
Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY grap…
products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate spe…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
ions, dependence on key personnel, protection of proprietary technologies, compliance with government regulations, ability to secure additional capital to fund operations, and potential delays associ…
MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC
MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC
62%
ct candidates ourselves. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our busine…
Aktis Oncology, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AKTS-DEBT
Debt stack $11.6M
90%
Market cache reports total debt of $11.6M.
AKTS-DEBT-59495
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2026-03-31.
Aktis Oncology, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aktis Oncology, Inc..
Aktis Oncology, Inc. Ownership
Holder
Name
Confidence
Evidence
AKTS-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 2 tracked holders.
Aktis Oncology, Inc. Extended Supply Chain Network
